The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human

Nanjing Medical University800 enrolled

Overview

To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Coronary Heart Disease, Susceptibility to, 1

Interventions

No interventionOTHER

This is an obvertional study, and there is no intervention.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with suspected coronary heart disease 2. patients received coronary angiography Exclusion Criteria: 1. NYHA III-IV 2. malignant tumor 3. acute infection 4. thyroid dysfunction

Locations (1)

Huai'an First People's Hospital

Huai'an, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

stenosis of coronary artery

The stenosis of coronary artery based on the results of coronary angiography

Time frame: 1 week

Secondary Outcomes

coronary artery calcium

The coronary artery calcification based on the results of coronary angiography

Time frame: 1 week

Central Contacts

Geng Jin, MD

CONTACT

+86-17753124846 gj885258@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.